Some very preliminary evidence suggests that Gingko biloba may be useful in treating behavioral problems in demented people. It is likely that the absence of regulatory controls on the sale of herbal buy OSI-744 and CAM preparations will foster continued use of these agents and perhaps even accelerated use as the dementia epidemic increases, assuming no imminent breakthroughs in pharmacotherapy.”
“Present work deals with the mercerization of Cannabis indica fibers and their subsequent surface modification
by aminopropyl triethoxysilane. The reaction parameters like time and concentration of the sodium hydroxide for mercerization were optimized. C. indica fibers treated with different silane concentration solutions were subjected to evaluation
of some of their properties like swelling behavior in different solvents, moisture absorbance under different humidity levels, and resistance toward chemicals such as sodium hydroxide and hydrochloric acid. C. indica fibers treated with 2% aminopropyl triethoxysilane solution have been found more resistant toward moisture, water, and chemicals when compared with that of untreated fibers. Morphological, structural changes, thermal stability, and crystallinity of both silane selleck compound treated and mercerized fibers have been studied by SEM, FTIR, TGA, and XRD techniques. Silane treatment has been found to cause decrease in crystallinity but increase in the thermal stability of the fibers. (C) 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2012″
“Purpose see more of review
Recombinant factor VIIa (rFVIIa) and thromboelastography have acquired increasing importance in patients with severe bleeding and coagulopathy. This article reviews the current opinions regarding their use, with the purpose of
clarifying the ambiguities that exist in dealing with trauma patients.
Recent findings
Recent evidence encourages the early use of rFVIIa and thromboelastography in the severe trauma patient with hemorrhagic shock, as a component of the damage control strategy. rFVIIa may decrease short-term mortality and the rate of required blood components during resuscitation, with no apparent increase in thromboembolic complications. Thromboelastometry enables better and earlier recognition of the coagulopathy accompanying such trauma patients. In patients with traumatic brain injury and coagulopathy, rFVIIa may delay or even halt the need for surgery, with no proven decrease in mortality. In those who needed urgent neurosurgical intervention, rFVIIa may rapidly correct the coagulopathy, enabling earlier and safer surgical intervention.
Summary
Thromboelastometry may guide the medical staff when and to whom rFVIIa could be administered. Evidence also encourages the use of rFVIIa in traumatic brain injury.